肺移植术后闭塞性细支气管炎诊治进展

doi:10.16138/j.1673-6087.2024.01.13

摘要/Abstract

摘要：

闭塞性细支气管炎综合征（bronchiolitis obliterans syndrome，BOS）是最常见的慢性肺移植物失功能的非感染形式。近年来，疾病早期0p期肺功能筛查、薄层CT扫描图像的小气道重建技术、³He-MRI等其他影像学检查技术、支气管肺泡灌洗液来源生物标志物等诊断方式近年来取得一定进展，目前对该类疾病认识有了较大更新。预防性使用阿奇霉素、再次肺移植以及脐血来源间充质干细胞等许多有潜力的治疗方式已经出现。BOS的综合诊断方式和潜在治疗策略的进展为该类疾病发生、发展的早期监测和管理提供了更多理论参考和见解。

关键词: 慢性肺移植物失功能, 闭塞性细支气管炎综合征, 慢性移植物抗宿主病

Abstract:

Bronchiolitis obliterans syndrome（BOS） is the most common non-infectious form of chronic lung allograft dysfunction. In recent years, diagnosis methods such as screening studies of lung function in the early 0p stage of the disease, small airway reconstruction techniques with thin-layer CT scan images, ³He-MRI and other imaging examination technique, and bronchoalveolar lavage-derived biomarkers are used, to make the understanding BOS to improve a lot. In terms of therapeutic strategies, many promising treatment modalities such as prophylactic azithromycin use, lung re-transplantation, and umbilical cord blood-derived mesenchymal stem cells have been applied. These advances in diagnostic methods and therapeutic strategies for occlusive bronchiolitis obliterans syndromes provide more theoretical references and insights into the early monitoring and management of the development of the disease.

Key words: Chronic lung transplant dysfunction, Bronchiolitis obliterans syndrome, Chronic graft versus host disease

中图分类号:

R562.2

朱海星, 周敏. 肺移植术后闭塞性细支气管炎诊治进展[J]. 内科理论与实践, 2024, 19(01): 72-76.

ZHU Haixing, ZHOU Min. Progress in diagnosis and treatment of obliterated bronchiolitis after lung transplantation[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(01): 72-76.

参考文献 32

[1]	Hakim A, Cooke KR, Pavletic SZ, et al. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally[J]. Bone Marrow Transplant, 2019, 54(3):383-392. doi: 10.1038/s41409-018-0266-6
[2]	Kulkarni HS, Cherikh WS, Chambers DC, et al. Bronchiolitis obliterans syndrome—free survival after lung transplantation[J]. J Heart Lung Transplant, 2019, 38(1):5-16. doi: 10.1016/j.healun.2018.09.016 URL
[3]	Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment[J]. J Heart Lung Transplant, 2019, 38(5):493-503. doi: 10.1016/j.healun.2019.03.009 URL
[4]	Abedin S, Yanik GA, Braun T, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung[J]. Biol Blood Marrow Transplant, 2015, 21(6):1127-1131. doi: 10.1016/j.bbmt.2015.02.006 URL
[5]	Driskel M, Horsley A, Fretwell L, et al. Lung clearance index in detection of post-transplant bronchiolitis obliterans syndrome[J]. ERJ Open Res, 2019, 5(4):00164-2019.
[6]	Nishimoto K, Karayama M, Inui N, et al. Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma[J]. Sci Rep, 2017, 7(1):10187. doi: 10.1038/s41598-017-10504-w pmid: 28860527
[7]	Davidsen JR, Laursen CB, Højlund M, et al. Lung ultrasound to phenotype chronic lung allograft dysfunction in lung transplant recipients[J]. J Clin Med, 2021, 10(5):1078. doi: 10.3390/jcm10051078 URL
[8]	Bos S, Milross L, Filby AJ, et al. Immune processes in the pathogenesis of chronic lung allograft dysfunction[J]. Eur Respir Rev, 2022, 31(165):220060. doi: 10.1183/16000617.0060-2022 URL
[9]	Berastegui C, Gómez-Ollés S, Sánchez-Vidaurre S, et al. BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients[J]. Clin Transplant, 2017, 31(3):e12898.
[10]	Nakashima M, Shinya T, Oto T, et al. Diagnostic value of ventilation/perfusion single-photon emission computed tomography/computed tomography for bronchiolitis obliterans syndrome in patients after lung transplantation[J]. Nucl Med Commun, 2019, 40(7):703-710. doi: 10.1097/MNM.0000000000001021 pmid: 31022070
[11]	Walkup LL, Myers K, El-Bietar J, et al. Xenon-129 MRI detects ventilation deficits in paediatric stem cell transplant patients unable to perform spirometry[J]. Eur Respir J, 2019, 53(5):1801779. doi: 10.1183/13993003.01779-2018 URL
[12]	Verleden SE, Gheysens O, Goffin KE, et al. Role of ¹⁸F-FDG PET/CT in restrictive allograft syndrome after lung transplantation[J]. Transplantation, 2019, 103(4):823-831. doi: 10.1097/TP.0000000000002393 pmid: 30086092
[13]	Shino MY, Li N, Todd JL, et al. Correlation between BAL CXCR3 chemokines and lung allograft histopathologies[J]. Am J Transplant, 2021, 21(10):3401-3410. doi: 10.1111/ajt.16601 URL
[14]	Itabashi Y, Ravichandran R, Bansal S, et al. Decline in club cell secretory proteins, exosomes induction and immune responses to lung self-antigens, Kα1 tubulin and collagen V, leading to chronic rejection after human lung transplantation[J]. Transplantation, 2021, 105(6):1337-1346. doi: 10.1097/TP.0000000000003428 URL
[15]	Berastegui C, Gómez-Ollés S, Mendoza-Valderrey A, et al. Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation[J]. PLoS One, 2020, 15(1):e0226488.
[16]	Ohshimo S, Bonella F, Sommerwerck U, et al. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation[J]. J Heart Lung Transplant, 2011, 30(12):1374-1380. doi: 10.1016/j.healun.2011.07.010 URL
[17]	Winkler A, Kahnert K, Behr J, et al. Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation[J]. Respir Res, 2018, 19(1):171. doi: 10.1186/s12931-018-0881-1
[18]	Siddiqui AS, Kumar G, Majumdar T, et al. Association of methacholine challenge test with diagnosis of chronic lung allograft dysfunction in lung transplant patients[J]. Clin Transplant, 2018, 32(10):e13397.
[19]	Bedair B, Hachem RR. Management of chronic rejection after lung transplantation[J]. J Thorac Dis, 2021, 13(11):6645-6653. doi: 10.21037/jtd-2021-19 pmid: 34992842
[20]	Hao X, Peng C, Lian W, et al. Effect of azithromycin on bronchiolitis obliterans syndrome in posttransplant recipients[J]. Medicine (Baltimore), 2022, 101(28):e29160.
[21]	Federica M, Nadia S, Monica M, et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection[J]. Clin Transplant, 2011, 25(4):E381-E389.
[22]	Mohseni R, Mahdavi Sharif P, Behfar M, et al. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)[J]. Stem Cell Res Ther, 2023, 14(1):256. doi: 10.1186/s13287-023-03498-y pmid: 37726865
[23]	Keller CA, Gonwa TA, Hodge DO, et al. Feasibility, safety, and tolerance of mesenchymal stem cell therapy for obstructive chronic lung allograft dysfunction[J]. Stem Cells Transl Med, 2018, 7(2):161-167. doi: 10.1002/sctm.17-0198 URL
[24]	January SE, Fester KA, Bain KB, et al. Rabbit antithymocyte globulin for the treatment of chronic lung allograft dysfunction[J]. Clin Transplant, 2019, 33(10):e13708.
[25]	Neurohr C, Kneidinger N, Ghiani A, et al. A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation[J]. Am J Transplant, 2022, 22(1):222-229. doi: 10.1111/ajt.16858 URL
[26]	Iacono A, Wijesinha M, Rajagopal K, et al. A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation[J]. ERJ Open Res, 2019, 5(4):00167-2019.
[27]	Sahakijpijarn S, Moon C, Ma X, et al. Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations[J]. Int J Pharm, 2020, 586:119490. doi: 10.1016/j.ijpharm.2020.119490 URL
[28]	Lebeer M, Kaes J, Lambrech M, et al. Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation[J]. Transpl Int, 2020, 33(2):216-228. doi: 10.1111/tri.v33.2 URL
[29]	Geng-Cahuayme AAA, Sáez-Giménez B, Altabas-González M, et al. Efficacy and safety of total lymphoid irradiation in different chronic lung allograft dysfunction phenotypes[J]. Clin Transplant, 2023, 37(2):e14891.
[30]	Benazzo A, Bagnera C, Ius F, et al. A European multi-center analysis of extracorporeal photopheresis as therapy for chronic lung allograft dysfunction[J]. Transpl Int, 2024, 36:11551. doi: 10.3389/ti.2023.11551 URL
[31]	Biswas Roy S, Panchanathan R, Walia R, et al. Lung retransplantation for chronic rejection[J]. Ann Thorac Surg, 2018, 105(1):221-227. doi: 10.1016/j.athoracsur.2017.07.025 URL
[32]	Ohsumi A, Tanaka S, Yamada Y, et al. Various combinations of living and deceased donors for lung retransplantation-a single institutional retrospective study[J]. Interdiscip Cardiovasc Thorac Surg, 2024, 38(1):ivae010.